USA's Enzon Pharmaceuticals buys sales rights to NatImmune compound  

US-based Biotech company Enzon Pharmaceuticals has bought sales rights to Copenhagen-based NatImmune's compound MBL

The US biotech company Enzon Pharmaceutical has bought the worldwide sales rights, excluding the Nordic region, to NatImmune's compound MBL. The agreement initially gives NatImmune DKK 62.5 mn (USD 10 mn), as well as milestone payments and royalties on possible future sales.

MBL [recombinant human Mannan Binding Lectin – Ed] is a plasma protein which plays a key role in first line immune defences against infection. The main indication for the drug is the prevention of severe infections in MBL deficient individuals receiving chemotherapy treatment. Enzon Pharmaceuticals will complete the development of the drug.

Martin Bonde, managing director of NatImmune is satisfied with the agreement, and says it marks a new chapter in the biotech company's development: "We have retained the rights to develop MBL for the treatment of skin diseases, and we will now proceed with that", he says.

NatImmune focuses on protein-based therapeutics for the prevention and treatment of infectious diseases and inflammation. The biotech firm is based in Symbion Science Park in Copenhagen. The largest investors in NatImmune are Novo A/S, the Employees Capital Pension Fund and Kommunernes Pensionsforsikring. The news was reported by financial daily newspaper Børsen and Erhvervsbladet.

Link > NatImmune 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×